###begin article-title 0
###xml 98 103 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphisms in the Regulatory Region of the Cyclophilin A Gene Influence the Susceptibility for HIV-1 Infection
###end article-title 0
###begin p 1
Conceived and designed the experiments: MAR NAK. Performed the experiments: MAR KAVD. Analyzed the data: MAR NAK. Wrote the paper: MAR NAK.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 149 154 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 272 277 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 339 344 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 384 387 <span type="species:ncbi:9606">men</span>
###xml 404 407 <span type="species:ncbi:9606">men</span>
###xml 409 412 <span type="species:ncbi:9606">MSM</span>
Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and disease progression. Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 478 481 478 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 12 24 <span type="species:ncbi:9606">participants</span>
###xml 197 200 <span type="species:ncbi:9606">MSM</span>
###xml 209 214 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 224 227 <span type="species:ncbi:9606">MSM</span>
###xml 316 319 <span type="species:ncbi:9606">MSM</span>
###xml 347 359 <span type="species:ncbi:9606">participants</span>
We screened participants of the ACS for the C1604G and A1650G polymorphisms in the regulatory regions of CypA. The prevalence of the 1650G allele was significantly higher in high risk seronegative MSM than in HIV-1 infected MSM. However, C1604G or A1650G were not associated with the clinical course of infection in MSM of the ACS. Interestingly, participants of the ACS-DU who carried the 1604G allele showed a significantly accelerated progression when viral RNA load above 104.5 copies per ml plasma was used as an endpoint in survival analysis.
###end p 5
###begin title 6
Conclusion/Significance
###end title 6
###begin p 7
###xml 153 158 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 126 129 126 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Braaten1">[1]</xref>
###xml 130 133 130 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Franke1">[3]</xref>
###xml 335 338 335 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Gamble1">[4]</xref>
###xml 340 343 340 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Braaten2">[5]</xref>
###xml 483 486 483 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Hatziioannou1">[6]</xref>
###xml 487 490 487 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Towers1">[9]</xref>
###xml 667 671 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Bosco1">[10]</xref>
###xml 120 125 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 176 181 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 646 651 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The peptidyl prolyl isomerase Cyclophilin A (CypA) is a cytoplasmic factor that is essential for efficient infection of HIV-1 [1]-[3]. It is specifically incorporated into the HIV-1 virion which is mediated through an interaction with the capsid protein of which an exposed loop between helices 4 and 5 mimic a natural ligand for CypA [4], [5]. Although CypA is incorporated in the virion, the presence of CypA in the target cell has the more significant effect on virus replication [6]-[9]. The molecular mechanism by which CypA enhances infection is largely unknown. CypA can catalyze the cis/trans isomerization of prolyl-peptide bonds in the HIV-1 capsid protein [10], which suggests that CypA has a possible role in uncoating of the viral core following entry into the cytoplasm.
###end p 9
###begin p 10
###xml 157 161 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Berthoux1">[11]</xref>
###xml 162 166 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Rits1">[14]</xref>
###xml 351 355 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Stremlau2">[15]</xref>
###xml 441 445 433 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Sayah1">[16]</xref>
###xml 447 451 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Nisole1">[17]</xref>
###xml 265 270 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recently, CypA has gained a lot of interest when it was identified as a cofactor for the tri-partite containing motif (Trim)5alpha in several simian species [11]-[14]. Trim5alpha is a retroviral restriction factor that associates with the capsid protein and blocks HIV-1 infection at an early step following entry of the viral core into the cytoplasm [15]. Moreover, Trim5-CypA fusion proteins have been discovered in several simian species [16], [17], suggesting that CypA in some instances can function as a capsid recognition domain for antiretroviral proteins.
###end p 10
###begin p 11
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-DeRodaHusman1">[18]</xref>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-vanRij1">[21]</xref>
###xml 590 594 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An1">[22]</xref>
###xml 595 599 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-vanManen1">[24]</xref>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 133 138 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 228 233 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphisms in human genes that serve as HIV-1 cofactors or restriction factors have been described to influence susceptibility to HIV-1 and disease progression. For example, polymorphisms in chemokine receptors that serve as HIV-1 coreceptors and their natural ligands have been associated with susceptibility to infection as well as disease progression [18]-[21]. Recently, polymorphisms in cellular factors like Apobec3G, CUL5 and Trim5alpha, that are directly or indirectly involved in innate immunity have also been demonstrated to have an effect on the clinical course of infection [22]-[24].
###end p 11
###begin p 12
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Bleiber1">[26]</xref>
###xml 344 349 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 470 475 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 505 510 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 524 536 <span type="species:ncbi:9606">participants</span>
###xml 572 577 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Previously 11 polymorphisms in the CypA gene have been identified none of which were located in the coding region of the gene [25]. Two of these SNPs (A1604G and C1650G) might affect CypA expression levels based on their location in the promoter region of the CypA gene and these polymorphism have been demonstrated to affect susceptibility to HIV-1 infection and disease progression [25], [26]. Here we studied the role of SNPs in the regulatory region of CypA gene on HIV-1 susceptibility and course of HIV-1 infection in participants of the Amsterdam Cohort Studies on HIV-1 infection and AIDS (ACS).
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 116 121 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distribution of the regulatory polymorphisms C1604G and A1650G in the CypA gene and the effect on susceptibility to HIV-1 infection
###end title 14
###begin p 15
###xml 424 431 424 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t001">Table 1</xref>
###xml 703 710 703 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t001">Table 1</xref>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 145 148 <span type="species:ncbi:9606">MSM</span>
###xml 171 174 <span type="species:ncbi:9606">MSM</span>
###xml 293 298 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 498 503 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 513 516 <span type="species:ncbi:9606">MSM</span>
###xml 541 553 <span type="species:ncbi:9606">participants</span>
###xml 686 691 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The haplotype frequency of polymorphisms C1604G and A1650G in the regulatory region of the CypA gene was studied in three groups: HIV-1 positive MSM of the ACS (n = 334), MSM of the ACS who remained seronegative despite reported high-risk behavior (High-risk seronegatives, HRSN; n = 68), and HIV-1 negative blood donors (controls) (n = 104). For all groups, genotype distributions and minor allele frequencies are shown in Table 1. Although a higher allele frequency of C1604G was observed in the HIV-1 infected MSM as compared to the HRSN participants and controls, this difference was not statistically significant indicating that the C1604G is not associated with susceptibility to HIV-1 infection (Table 1).
###end p 15
###begin title 16
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genotype distributions of the CypA SNPs C1604G and A1650G and risk for HIV-1 infection.
###end title 16
###begin p 17
MAJ = major genotype; HZ = heterozygous genotype; MIN = minor genotype.
###end p 17
###begin p 18
###xml 109 114 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 124 127 <span type="species:ncbi:9606">MSM</span>
###xml 215 220 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 234 246 <span type="species:ncbi:9606">participants</span>
The minor allele frequency of the A1650G polymorphism in the HRSN was significantly increased as compared to HIV-1 positive MSM, suggesting that the 1650G allele may be associated with a decreased susceptibility to HIV-1 infection in participants of the ACS.
###end p 18
###begin title 19
Effects of regulatory CypA polymorphisms on disease progression
###end title 19
###begin p 20
###xml 362 366 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Centers1">[27]</xref>
###xml 368 372 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Centers2">[28]</xref>
###xml 406 409 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 649 656 645 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t002">Table 2</xref>
###xml 106 111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 121 124 <span type="species:ncbi:9606">MSM</span>
###xml 585 588 <span type="species:ncbi:9606">MSM</span>
###xml 780 785 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 795 798 <span type="species:ncbi:9606">MSM</span>
Next, we examined the influence of polymorphisms C1604G and A1650G on the clinical course of infection in HIV-1 positive MSM of the ACS. Kaplan Meier and Cox proportional hazard analyses were used to test for potential differences in rates of progression to CD4+ T cells below 200 cells per microl, clinical AIDS according to the CDC definition of 1987 and 1993 [27], [28] or plasma viral RNA load above 104.5 copies per ml between individuals who carried the major or minor allele (dominant model). The C1604G and the A1650G polymorphisms were not associated with survival time among MSM of the ACS, independent of the endpoints used for analysis (Table 2). In addition, both polymorphisms were also not associated with CD4+ T cell number or plasma viral RNA load at setpoint in HIV-1 positive MSM (data not shown).
###end p 20
###begin title 21
###xml 89 92 <span type="species:ncbi:9606">MSM</span>
Effects of CypA SNPs C1604G and A1650G on disease progression in the Amsterdam cohort of MSM.
###end title 21
###begin p 22
P-values were from Cox proportional hazard analysis.
###end p 22
###begin p 23
###xml 445 452 445 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t001">Table 1</xref>
Similar analyses were performed in the ACS of drug users (DU, n = 120). In this cohort, 9% of the individuals were heterozygous for C1604G (minor allele frequency of 0.046) and 25.4% were heterozygous for A1650G (minor allele frequency of 0.129). None of the individuals was homozygous for either 1604G or 1650G. The minor allele frequency for the C1604G and A1650G polymorphism among DU was similar to the frequencies observed in the controls (Table 1).
###end p 23
###begin p 24
###xml 193 200 189 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t003">table 3</xref>
###xml 331 334 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 416 424 412 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003975-g001">Figure 1</xref>
###xml 426 433 422 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t003">table 3</xref>
###xml 548 551 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 612 620 608 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003975-g001">Figure 1</xref>
###xml 622 629 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003975-t003">table 3</xref>
###xml 8 20 <span type="species:ncbi:9606">participants</span>
Also in participants of the ACS-DU, the minor alleles of C1604G and A1650G were not associated with progression to a first CD4+ T cell count below 200 cells per microl blood, or clinical AIDS (table 3). However, carriers of the minor allele of C1604G showed a significantly accelerated progression towards a viral RNA load above 104.5 copies per ml plasma (log rank p = 0.007, RH 2.55, CI95% 1.252-5.171; p = 0.01) (Figure 1, table 3). DU carrying the A1650G minor allele tended to have a somewhat slower progression towards viral RNA load above 104.5 copies per ml plasma, albeit not statistically significant (Figure 1, table 3). No significant association between CD4+ T-cells or RNA setpoint and the C1604G or A1650G polymorphism was observed (data not shown).
###end p 24
###begin title 25
Survival analysis for C1604G and A1650G in DU of the ACS.
###end title 25
###begin p 26
###xml 87 90 87 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
Kaplan Meier analysis for time in months from seroconversion to viral RNA load above 104.5 copies per ml plasma in DU of the ACS based on the C1604G genotype (left panel) or A1650G genotype (right panel). Black lines indicate individuals homozygous for the major allele (left panel: 1604CC; right panel: 1650AA); Gray lines indicate individuals heterozygous for the minor allele (left panel: 1604CG; right panel: 1650AG).
###end p 26
###begin title 27
Effects of CypA SNPs C1604G and A1650G on disease progression in DU of the Amsterdam cohort.
###end title 27
###begin p 28
P-values were from Cox proportional hazard analysis.
###end p 28
###begin title 29
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of regulatory polymorphisms in CypA on CypA expression levels and HIV-1 replication
###end title 29
###begin p 30
###xml 541 549 541 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003975-g002">figure 2</xref>
Next we analyzed whether the C1604G and A1650G polymorphisms in the regulatory regions of the CypA gene were associated with altered CypA expression levels. To this end, we performed quantitative RT-PCR on CypA mRNA levels in peripheral blood mononuclear cells (PBMC) of 28 healthy blood donors genotyped for the C1604G and A1650G polymorphism. We observed a reduced CypA expression in PBMC that were heterozygous for the 1604G minor allele as compared to PBMC that were homozygous for the major allele (1604C) (Unpaired T-test; P = 0.023) (figure 2). No differences in CypA expression were observed in PBMC heterozygous for the 1650G minor allele compared to PBMC homozygous for the 1650A major allele.
###end p 30
###begin title 31
Analysis of CypA expression levels.
###end title 31
###begin p 32
CypA mRNA levels in PBMC obtained from healthy controls that were homozygous for the 1604 and 1650 major alleles (1604CC/1650AA), heterozygous for the 1604 minor allele (1604CG), or heterozygous for the 1650 minor allele (1650AG). CypA mRNA levels were normalized for beta-actin mRNA levels.
###end p 32
###begin p 33
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 224 226 224 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 568 576 568 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003975-g003">figure 3</xref>
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Next, we analyzed the replicative capacity of HIV-1 in PHA-stimulated PBMC from healthy individuals with known genotypes for the C1604G and A1650G polymorphism. PHA-stimulated PBMC were inoculated with NL4-3 Ba-L (2x103 TCID50 per 5x106 cells). Subsequently, virus replication was assessed by measuring p24 antigen levels in the culture supernatant every other day for a period of two weeks. No significant differences in p24 production were observed at any time point during the culture period, irrespective of the genotype of the regulatory region of the CypA gene (figure 3).
###end p 33
###begin title 34
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Analysis of HIV-1 replication in genotyped PBMC.
###end title 34
###begin p 35
Replication of NL4-3 Ba-L in PHA stimulated PBMC from healthy donors homozygous for the 1604 and 1650 major allele (1604CC/1650AA), heterozygous for the 1604 minor allele (1604CG), or heterozygous for the 1650 minor allele (1650AG). Virus replication was analyzed by measuring p24 production in culture supernatant. P24 production at day 12 after infection is shown.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Luban1">[2]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Sayah1">[16]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Nisole1">[17]</xref>
###xml 320 324 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Berthoux1">[11]</xref>
###xml 325 329 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Rits1">[14]</xref>
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 439 444 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 482 494 <span type="species:ncbi:9606">participants</span>
CypA has been identified as a cofactor for HIV-1, leading to enhanced infection by a largely unknown mechanism [2]. The identification of Trim5-CypA fusion proteins as restriction factors [16], [17] and the dependency of Rhesus Trim5alpha on CypA has renewed the interest in this ubiquitously expressed cellular protein [11]-[14]. Here we analyzed the effects of polymorphisms in the promoter region of the CypA gene on susceptibility for HIV-1 infection and disease progression in participants of the ACS.
###end p 37
###begin p 38
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Bleiber1">[26]</xref>
###xml 225 230 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 250 253 <span type="species:ncbi:9606">MSM</span>
###xml 406 411 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In a previous study, 1604G was observed to be associated with a more rapid CD4+ T-cell decline in African Americans and a trend towards more rapid progression to AIDS was observed in European Americans [25]. In our cohort of HIV-1 positive Caucasian MSM, no association between 1604G and progression to AIDS or any other endpoint was observed. This is in agreement with observations in the Swiss cohort of HIV-1 infected individuals who are also all Caucasian [26].
###end p 38
###begin p 39
###xml 327 330 323 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In the ACS on HIV-1 infected drug users, we could also not demonstrate an association between polymorphisms in the regulatory region of the CypA gene and survival to CD4+ T-cell counts below 200 cells per microl or AIDS according to the 1987 and 1993 definitions. In this cohort, however, time to plasma viral RNA load above 104.5 copies per ml was significantly reduced in 1604G carriers. These observations suggest only a minor effect of polymorphisms in the regulatory region of CypA which may become apparent only during the late stages of infection when viral load is increasing.
###end p 39
###begin p 40
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Bleiber1">[26]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 1015 1019 1015 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 339 344 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 520 523 <span type="species:ncbi:9606">MSM</span>
###xml 586 589 <span type="species:ncbi:9606">MSM</span>
###xml 670 675 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 685 688 <span type="species:ncbi:9606">MSM</span>
###xml 779 784 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1071 1076 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A second polymorphism in the regulatory region of the CypA promoter involves position 1650. In a Swiss Caucasian cohort, 1650G was reported to be associated with a rapid CD4+ T cell loss and enhanced progression to disease [26]. An association between the presence of 1650G and delayed disease progression was also observed in a cohort of HIV-1 infected African Americans and a trend towards a delayed progression to AIDS was observed in European Americans [25]. We were unable to confirm these results in our cohort of MSM. However, we did observe an enrichment of the 1650G allele in MSM who have remained seronegative despite high risk behavior (HRSN) as compared to HIV-1 infected MSM which might indicate that the 1650G allele is associated with a reduced susceptibility to HIV-1 infection. This contradicts findings of an earlier study where a reduced prevalence of the 1650G allele was observed in European Americans who remained seronegative despite high risk behavior as compared to a seroconverter cohort [25]. Furthermore, no effect of the 1650G allele on the HIV-1 susceptibility and replication was observed in an in vitro replication assay using PHA stimulated PBMC from donors who were homozygous for the 1650A allele or heterozygous for the 1650G allele. However, in vitro infection of PHA stimulated PBMC may be not reflective of in vivo transmission conditions.
###end p 40
###begin p 41
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Bleiber1">[26]</xref>
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-DeRodaHusman1">[18]</xref>
###xml 773 777 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Schinkel1">[29]</xref>
###xml 279 284 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 448 453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 480 485 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 652 657 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 667 670 <span type="species:ncbi:9606">MSM</span>
###xml 744 749 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The observed differences between our present study and earlier reports [25], [26] may be explained by differences in the study populations. Interactions with other sequence variations that are distributed differently between the populations, immunological differences, different HIV-1 transmission routes, and differences in the circulating virus populations may account for the variable outcomes of these studies. Variations in natural history of HIV-1 infection among different HIV-1 infected cohorts have been reported before. For example, heterozygosity for the 32 basepair deletion in the CCR5 gene has a strong protective effect in the cohort of HIV-1 infected MSM of the ACS [18] whereas no effect on disease progression was observed in HIV-1 infected DU of the ACS [29].
###end p 41
###begin p 42
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Palacin1">[30]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-An3">[25]</xref>
###xml 876 881 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphisms in the promoter region of CypA may have an effect on the CyPA expression levels and recently it was demonstrated that the 1604G allele enhances binding of transcription factors such as SP1, resulting in increased transcription of the CypA gene [25], [30]. Seemingly in contrast, we here observed a reduction in CypA expression in PBMC isolated from healthy C1604G heterozygous blood donors when compared to PBMC from carriers of the major allele. However, another polymorphism in the regulatory region of CypA, (C1575G), which is in 100% linkage disequilibrium with the C1604G polymorphism, was shown to reduce nuclear factor binding and decrease transcription of CypA [25]. Our results may thus indicate that the effect of these polymorphisms on CypA transcription is dominated by 1575G allele. However, the reduction in CypA expression levels had no effect on HIV-1 replication in vitro using PHA stimulated PBMC from donors who were homozygous or heterozygous for the C1604G genotype.
###end p 42
###begin p 43
###xml 214 219 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Overall, we here show that polymorphisms in the regulatory region of the CypA are only weakly associated with the clinical course of infection in the ACS. However, considering the important role of this protein in HIV-1 replication, manipulation of CypA activity by therapeutic intervention should be seriously considered.
###end p 43
###begin title 44
Materials and Methods
###end title 44
###begin title 45
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 45
###begin p 46
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-DeRodaHusman1">[18]</xref>
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Geskus1">[31]</xref>
###xml 1020 1024 1020 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-vanRij1">[21]</xref>
###xml 37 40 <span type="species:ncbi:9606">MSM</span>
###xml 114 119 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 295 306 <span type="species:ncbi:9606">participant</span>
###xml 339 351 <span type="species:ncbi:9606">participants</span>
###xml 407 410 <span type="species:ncbi:9606">men</span>
###xml 429 434 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 629 634 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 653 656 <span type="species:ncbi:9606">MSM</span>
###xml 787 799 <span type="species:ncbi:9606">participants</span>
###xml 853 865 <span type="species:ncbi:9606">participants</span>
###xml 1035 1047 <span type="species:ncbi:9606">participants</span>
The study population, 364 Caucasian, MSM enrolled in the Amsterdam Cohort studies (ACS) on the natural history of HIV-1 infection between October 1984 and March 1986, was previously described [18]. The censor date of our study was set at the first day of effective antiretroviral therapy of the participant or end of follow-up. Of the 364 participants, 131 seroconverted during the study. The remaining 233 men were positive for HIV-1 antibodies at entry between October 1984 and April 1985. In previous epidemiological studies, the time since seroconversion of these prevalent cases has been estimated based on the incidence of HIV-1 infection amongst MSM of the Amsterdam Cohort and was on average 1.5 years before entry into the cohort studies [31]. For analysis, we combined the 131 participants with documented seroconversion and 233 seroprevalent participants with an imputed seroconversion date as one study group, since previous studies have not revealed differences in AIDS-free survival between the two groups [21]. From 334 participants DNA samples were available for analysis.
###end p 46
###begin p 47
###xml 12 15 <span type="species:ncbi:9606">MSM</span>
###xml 67 70 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Sixty-eight MSM with high-risk behavior that persistently remained HIV-seronegative (HRSN) were retrospectively selected from the ACS. They remained seronegative during a follow up of 5 years before January 1996 and had reported unprotected receptive anal intercourse with at least 2 different partners before January 1996 (introduction of highly active antiretroviral therapy (HAART)).
###end p 47
###begin p 48
###xml 1227 1231 1227 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Geskus1">[31]</xref>
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 137 140 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 225 228 <span type="species:ncbi:9606">men</span>
###xml 233 238 <span type="species:ncbi:9606">women</span>
###xml 413 418 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 519 522 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 788 791 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 944 961 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 1126 1129 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1146 1149 <span type="species:ncbi:9606">men</span>
###xml 1157 1162 <span type="species:ncbi:9606">women</span>
A second study population consists of 120 HIV-1 infected intravenous drug users (DU) that participate in the Amsterdam Cohort Studies on HIV and AIDS among intravenous drug users which started enrolment in 1985. Asymptomatic men and women who were living in the Amsterdam area and who reported intravenous drug use in the preceding 6 months were enrolled in a prospective study on the prevalence and incidence of HIV-1 infection and risk factors for AIDS. In our study, we included 84 individuals who seroconverted for HIV antibodies during active follow-up. The median time between the last negative test and the first positive test for this group of prospective seroconverters was 3.9 months (interquartile range, 3.7-5.1). At entry in the cohort study 37 individuals were positive for HIV antibodies but had a negative test result before entry (i.e., retrospective seroconverters). Negative test results were obtained from samples taken for hepatitis B virus serology. The median interval between the last negative and first positive tests was 4.1 years (interquartile range, 1.8-5.4) for these seroconverters. For all 120 HIV infected DU (76 men and 44 women) used for our present analysis, the imputed seroconversion date [31] was calculated and used for further analysis.
###end p 48
###begin p 49
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Healthy volunteer blood donors (n = 104) were used as HIV-1 negative control group. The ACS has been conducted in accordance with the ethical principles set out in the declaration of Helsinki and written informed consent is obtained prior to data collection. The study was approved by the Academic Medical Center institutional medical ethics committee.
###end p 49
###begin title 50
Genotyping for regulatory polymorphisms in CypA
###end title 50
###begin p 51
###xml 299 333 299 333 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCACTGTCACTCTGGCGAAGTCGCAGAC-3&#8242;</named-content>
###xml 346 377 346 377 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCGAGCACGTGCGTCGGACAGGAC-3&#8242;</named-content>
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 24 27 <span type="species:ncbi:9606">MSM</span>
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
DNA samples of 334 HIV+ MSM, 68 HRSN, 120 HIV+ DU and 104 healthy controls were available for genotyping. For analysis of the polymorphism in the promoter region of CypA, DNA samples were amplified by PCR using Taq DNA polymerase (Invitrogen) in the presence of 3 mM MgCl with primer pair C1604G-F (5'-GCACTGTCACTCTGGCGAAGTCGCAGAC-3') and P4H-R (5'-GCCGAGCACGTGCGTCGGACAGGAC-3'). The following amplification cycles were used: 5 min 95degreesC; 40 cycles of 30 s 95degreesC, 45 s 65degreesC, 60 s 72degreesC; 10 min 72degreesC. Subsequently PCR products were subjected to a restriction digest with 1U BstN1 (1 hour 60degreesC; New England Biolabs) to detect the C1604G polymorphism or with 10U Rsa1 (1 hour 37degreesC; New England Biolabs) to detect the A1650G polymorphism and analyzed on a 1.25% agarose gel. A PCR product containing a C at position 1604 or a G at position 1650 will result in a 524 bp fragment (undigested) product. A PCR product containing a C at position 1604 will result in digestion of the PCR product by BstN1 into a 423 bp and 101 bp fragments. A PCR product containing an A at position 1650 will be digested with Rsa1 resulting in a 369 bp and 55 bp fragments.
###end p 51
###begin title 52
CypA expression analysis and in vitro replication assay
###end title 52
###begin p 53
###xml 512 513 503 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 754 780 737 763 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTTCATCCTAAAGCATACGG-3&#8242;</named-content>
###xml 794 818 777 801 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTTCTTGCTGGTCTTGCC-3&#8242;</named-content>
###xml 1055 1085 1035 1065 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCCCAGTCCTCTCCCAAGTCCAC-3&#8242;</named-content>
###xml 1099 1128 1079 1108 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGTAAGCCCTGGCTGCCTCCACC-3&#8242;</named-content>
Cells from 28 healthy blood donors were isolated, genotyped for C1604G and A1650G and the CypA expression levels were measured by real time Light cycler PCR. RNA was isolated by Trizol (Invitrogen) according to the manufacturer's protocol. Subsequently, cDNA was prepared using the SuperScripttrade mark First-Strand Synthesis System for RT-PCR (Invitrogen). CypA mRNA levels were analyzed by SYBR green qPCR using the LightCycler (Roche). The reaction mix contained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 3 mM MgCl2, 200 microM dNTP, 250 microg/ml BSA, 500 nM primers, SYBR green I nucleic acid gel stain 40.000x diluted in water, and 0.6 U platinum Taq DNA polymerase (Invitrogen). The following primer sets were used for detection of CypA cDNA: CypA-2F: 5'-CTTCATCCTAAAGCATACGG-3' and CypA-2R: 5'-CTTCTTGCTGGTCTTGCC-3'. Serial dilutions of plasmid DNA containing cDNA of CypA were used as a standard curve. To correct for differences in the cDNA input, levels of beta-actin cDNA were analyzed by a SYBR green qPCR using the following primer set: BA-RNA-F 5'-GGCCCAGTCCTCTCCCAAGTCCAC-3' and BA-RNA-R 5'-GGTAAGCCCTGGCTGCCTCCACC-3'. A serial dilution of 8E5 cells was used as a standard curve for beta-actin. SYBR green qPCR was performed using the following program on the LightCycler: (1) preincubation and denaturation: 50degreesC for 2 min, 95degreesC for 2 min; (2) amplification and quantification: 45 cycles of 95degreesC for 5 sec, 55degreesC for 15 sec, 72degreesC for 15 sec; (3) melting curve: 95degreesC for 0 sec, 65degreesC for 15 min, 95degreesC for 0 sec with a temperature transition rate of 0.1degreesC/sec. Specificity of the PCR products measured using the SYBR green method was confirmed by a melting curve.
###end p 53
###begin p 54
###xml 275 276 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 566 568 558 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 738 742 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Tersmette1">[32]</xref>
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 384 388 <span type="species:ncbi:9913">calf</span>
The replicative capacity of HIV-1 in PBMC from healthy blood donors that were genotyped for C1604G and A1650G was investigated. PBMC were isolated from buffy coats obtained from healthy seronegative blood donors by Ficoll-isopaque density gradient centrifugation. Cells (5x106/ml) were stimulated for 2 days in Iscove's modified Dulbecco medium (Whitaker) supplemented with 10% fetal calf serum (Hyclone), penicillin (Gibco Brl) (100 U/ml), streptomycin (Gibco Brl) (100 microg/ml) and phytohemagglutinin (Welcome) (5 microg/ml). Cells were inoculated with 2000 TCID50 NL4-3(Ba-L) and replication was assessed by measuring virus production in culture supernatants by in-house p24 antigen capture enzyme-linked immunosorbent assay (ELISA) [32].
###end p 54
###begin title 55
Statistical analysis
###end title 55
###begin p 56
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Centers1">[27]</xref>
###xml 771 775 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003975-Centers2">[28]</xref>
###xml 858 861 854 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 943 948 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Statistical analysis was performed employing SPSS (version 16). The genetic effects of SNPs on HIV-1 susceptibility were assessed by comparing the allelic and genotypic frequencies between susceptibility groups using the Pearson chi square test. The minor allele frequencies were compared to the most common genotype as a reference group. Kaplan Meier and Cox proportional hazard analysis were performed to study the genotypic association and relative hazard (RH) between the C1604G and A1650G polymorphisms in the regulatory regions of the CypA gene and disease progression. The following endpoints were considered for analysis: 1) AIDS according to the 1987 Centers for Disease Control and Prevention (CDC) definition [27]; 2) AIDS according to the 1993 CDC definition [28]; 3) CD4+ T cell counts below 200 cells/microl blood and 4. Viral RNA load above 104.5 copies per ml plasma. CypA expression and differences in replicative capacity of HIV-1 in genotyped donor PBMC were compared using the student T-test. A result was considered significant if the P-value was <0.05.
###end p 56
###begin p 57
###xml 74 79 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 331 343 <span type="species:ncbi:9606">participants</span>
This study was performed as part of the Amsterdam Cohort Studies (ACS) on HIV-1 infection and AIDS, a collaboration between the Amsterdam Health Service, the Academic Medical Center of the University of Amsterdam, Sanquin Blood Supply Foundation, and the University Medical Center Utrecht (). We are greatly indebted to all cohort participants for their continuous participation. The authors thank Jodie Kamati for excellent technical assistance and Hanneke Schuitemaker for helpful discussion and critical reading of the manuscript.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.
###end article-title 59
###begin article-title 60
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.
###end article-title 60
###begin article-title 61
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Specific incorporation of cyclophilin A into HIV-1 virions.
###end article-title 61
###begin article-title 62
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.
###end article-title 62
###begin article-title 63
###xml 66 101 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.
###end article-title 63
###begin article-title 64
###xml 39 74 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.
###end article-title 64
###begin article-title 65
###xml 36 71 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.
###end article-title 65
###begin article-title 66
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.
###end article-title 66
###begin article-title 67
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors.
###end article-title 67
###begin article-title 68
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A.
###end article-title 68
###begin article-title 69
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells.
###end article-title 69
###begin article-title 70
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.
###end article-title 70
###begin article-title 71
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1.
###end article-title 71
###begin article-title 72
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein.
###end article-title 72
###begin article-title 73
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.
###end article-title 73
###begin article-title 74
###xml 53 63 <span type="species:ncbi:9505">owl monkey</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.
###end article-title 74
###begin article-title 75
###xml 46 56 <span type="species:ncbi:9505">owl monkey</span>
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1.
###end article-title 75
###begin article-title 76
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Association between CCR5 genotype and the clinical course of HIV-1 infection.
###end article-title 76
###begin article-title 77
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression.
###end article-title 77
###begin article-title 78
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant.
###end article-title 78
###begin article-title 79
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection.
###end article-title 79
###begin article-title 80
APOBEC3G genetic variants and their influence on the progression to AIDS.
###end article-title 80
###begin article-title 81
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals.
###end article-title 81
###begin article-title 82
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection.
###end article-title 82
###begin article-title 83
Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS.
###end article-title 83
###begin article-title 84
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 99 134 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression.
###end article-title 84
###begin article-title 85
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome.
###end article-title 85
###begin article-title 86
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
###end article-title 86
###begin article-title 87
###xml 81 86 <span type="species:ncbi:9606">Human</span>
###xml 118 123 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
No evidence for an effect of the CCR5 Delta32/+ and the CCR2b 64I/+ mutations on Human Immunodeficiency Virus type 1 (HIV-1) disease progression disease progression among HIV-1 infected injecting drug users.
###end article-title 87
###begin article-title 88
A search for cyclophilin-A gene (PPIA) variation and its contribution to the risk of atherosclerosis and myocardial infarction.
###end article-title 88
###begin article-title 89
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion.
###end article-title 89
###begin article-title 90
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 97 100 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag.
###end article-title 90
###begin p 91
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 91
###begin p 92
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Netherlands Organization for scientific Research (NWO grant number 96.36.024); the Dutch AIDS fund (grant 2004062) and the Landsteiner Foundation for Blood Transfusion Research (grant 0435). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 92

